Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF regimen) in patients with metastatic colorectal cancer: The southern Italy cooperative oncology group experience

Pasquale Comella, Bruno Massidda, Donato Natale, Carlo Putzu, Claudia Sandomenico, Gianfranco Filippelli, Sergio Palmeri, Giovanni Condemi, Giacomo Vessia, Giuseppe Barberis, Maria Teresa Ionta, Salvatore Tafuto, Enrico Barbato

Research output: Contribution to journalArticlepeer-review

Abstract

We have extensively assessed a biweekly regimen of irinotecan plus folinic acid and fluorouracil bolus (IRIFAFU) in metastatic colorectal cancer (MCRC). Here, we report on the safety and activity of BIFF (bevacizumab plus IRIFAFU) regimen in 94 mCRC patients. Bevacizumab 5 mg/kg (1 hour), and irinotecan 180 mg/m2 (1hour) were given intravenously on day 1, 6S-folinic acid 250 mg/m2 (2 hours), and fluorouracil 850 mg/m2 (bolus) were given intravenously on day 2 every 2 weeks for a median of 9 cycles per patient (range, 1-12), and maintenance bevacizumab alone was delivered in 16 cases. Grade ≥ 3 hematologic toxicities were neutropenia (50%) and febrile neutropenia (5%). Most common grade 3 nonhematologic side effects were diarrhea (20%), vomiting (7%), nausea (4%), and stomatitis (4%). Severe hypertension (1%) and epistaxis (1%) rarely occurred. Six complete responses and 44 partial responses were registered, giving a response rate of 53% (95% CI, 43%-64%). Median progression-free survival was 11.5 months (95% CI, 9.0-14.0 months). Forty-three (46%) patients eventually died, and the median overall survival was 24.0 months (95% CI, 20.2-27.8 months). Bevacizumab appeared to increase the activity of the IRIFAFU regimen without worsening its tolerability. Efficacy of BIFF was comparable with that reported with other bevacizumab plus irinotecan-based combinations.

Original languageEnglish
Pages (from-to)42-47
Number of pages6
JournalClinical Colorectal Cancer
Volume10
Issue number1
DOIs
Publication statusPublished - 2011

Keywords

  • Combination regimen
  • IRIFAFU

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF regimen) in patients with metastatic colorectal cancer: The southern Italy cooperative oncology group experience'. Together they form a unique fingerprint.

Cite this